HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Consensus Price Target of $14.87 According to Analysts

Posted by Stanley Muller on Nov 12th, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM – Get Free Report) has received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $14.87.

HCM has been the subject of a number of analyst reports. The Goldman Sachs Group cut their target price on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, July 23rd. Daiwa Securities Group upgraded HUTCHMED from a “hold” rating to a “buy” rating in a research report on Thursday, September 3rd. Wall Street Zen upgraded shares of HUTCHMED from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. HSBC raised shares of HUTCHMED from a “hold” rating to a “buy” rating in a report on Tuesday, September 8th. Finally, Weiss Ratings upgraded HUTCHMED from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, October 20th.

View Our Latest Analysis on HUTCHMED

Hedge Funds Weigh In On HUTCHMED

Hedge funds have recently bought and sold shares of the stock. XY Capital Ltd raised its stake in HUTCHMED by 115.2% in the 2nd quarter. XY Capital Ltd now owns 104,130 shares of the company’s stock valued at $1,120,000 after purchasing an additional 55,736 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of HUTCHMED in the first quarter valued at $365,000. Amundi increased its stake in HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after purchasing an additional 8,916 shares during the last quarter. Finally, Crossmark Global Holdings Inc. boosted its stake in HUTCHMED by 25.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 106,185 shares of the company’s stock worth $1,553,000 after buying an additional 21,270 shares during the last quarter. Hedge funds and other institutional investors own 8.82% of the company’s stock.

HUTCHMED Trading Down 2.0%

HCM stock opened at $15.08 on Friday. HUTCHMED has a one year low of $9.77 and a one year high of $16.33. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64. The company has a fifty day moving average of $13.99 and a 200-day moving average of $13.20.

About HUTCHMED

(Get Free Report)

HUTCHMED is a biopharmaceutical company focused on discovering, developing and commercializing medicines, particularly targeted therapies for cancer. Founded in 2000 as Hutchison China MediTech, the company adopted the HUTCHMED name in 2021. Its oncology medicines include fruquintinib, marketed in China as Elunate and in the United States and other markets as Fruzaqla through a partner; surufatinib, marketed in China as Sulanda; and savolitinib, marketed in China as Orpathys. The company also maintains a pipeline of investigational medicines for cancer and immunological diseases.